These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 2416823

  • 1. Changes in thymocyte proliferation at different stages of viral leukemogenesis in AKR mice.
    O'Donnell PV, Traganos F.
    J Immunol; 1986 Jan; 136(2):720-7. PubMed ID: 2416823
    [Abstract] [Full Text] [Related]

  • 2. Stages in development of mink cell focus-inducing (MCF) virus-accelerated leukemia in AKR mice.
    O'Donnell PV, Woller R, Chu A.
    J Exp Med; 1984 Sep 01; 160(3):914-34. PubMed ID: 6236277
    [Abstract] [Full Text] [Related]

  • 3. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
    Green WR.
    J Immunol; 1983 Dec 01; 131(6):3078-84. PubMed ID: 6605998
    [Abstract] [Full Text] [Related]

  • 4. The effects of leukemosuppressive immunotherapy on thymic infectious cell centers in AKR mice.
    Buckheit RW, Liberman SN, Bolognesi DP, Weinhold KJ.
    Thymus; 1983 Dec 01; 12(3):143-56. PubMed ID: 3266951
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development of lymphoma in the thymus of AKR mice treated with the lymphomagenic virus SL 3-3.
    Hays EF, Bristol GC, McDougall S, Klotz JL, Kronenberg M.
    Cancer Res; 1989 Aug 01; 49(15):4225-30. PubMed ID: 2545338
    [Abstract] [Full Text] [Related]

  • 7. Antigens shared by thymic stromal cells and T lymphocytes are abnormally expressed in AKR thymuses.
    Tucek CL, Boyd RL, Hiai H.
    Thymus; 1989 Aug 01; 14(1-3):95-107. PubMed ID: 2623744
    [Abstract] [Full Text] [Related]

  • 8. Clonal heterogeneity of anti-AKR/gross leukemia virus cytotoxic T lymphocytes. Evidence for two distinct antigen systems.
    Azuma H, Phillips JD, Green WR.
    J Immunol; 1987 Oct 01; 139(7):2464-73. PubMed ID: 2821116
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Heterogeneity of immature (Lyt-2-/L3T4-) thymocytes. Identification of four major phenotypically distinct subsets differing in cell cycle status and in vitro activation requirements.
    Howe RC, MacDonald HR.
    J Immunol; 1988 Feb 15; 140(4):1047-55. PubMed ID: 3257768
    [Abstract] [Full Text] [Related]

  • 14. Genetic control of the induction of cytolytic T lymphocyte responses to AKR/Gross viral leukemias. I. H-2-encoded dominant gene control.
    Green WR.
    J Immunol; 1984 May 15; 132(5):2658-64. PubMed ID: 6425409
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon.
    Bekesi JG, Roboz JP, Zimmerman E, Holland JF.
    Cancer Res; 1976 Feb 15; 36(2 pt 2):631-9. PubMed ID: 1082796
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Expression of CTL-defined, AKR/Gross retrovirus-associated tumor antigens by normal spleen cells: control by Fv-1, H-2, and proviral genes and effect on antiviral CTL generation.
    Green WR.
    J Immunol; 1986 Jan 15; 136(1):308-12. PubMed ID: 2999246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.